ʻO nā Cellular Therapies ka hope o ka maʻi autoimmune?

Hiki ke mālama a hoʻihoʻi hou i ka ʻōnaehana pale e hāʻawi i ke kala lōʻihi a i ʻole hoʻōla i kekahi mau maʻi autoimmune.

Ua hāʻawi ʻo Chimeric antigen receptor (CAR) T-cell therapy i kahi ala hou no ka mālama ʻana i nā maʻi maʻi hematologic mai 2017, akā aia nā hōʻailona mua e hiki ke hana hou ʻia kēia mau immunotherapies cellular no nā maʻi autoimmune mediated B-cell.

I Kepakemapa o ka makahiki i hala, ua hōʻike nā mea noiʻi ma Kelemania he ʻelima mau maʻi me ka refractory systemic lupus erythematosus (SLE) i mālama ʻia me CAR T-cell therapy i loaʻa i ke kala kala ʻole. I ka manawa o ka paʻi ʻana, ʻaʻohe mea maʻi i hoʻi hou a hiki i 17 mau mahina ma hope o ka mālama ʻana. Ua wehewehe nā mea kākau i ka seroconversion o nā antibodies antinuclear i ʻelua mau maʻi me ka lōʻihi o ka hahai ʻana, "e hōʻike ana i ka hoʻopau ʻana i nā clones B-cell autoimmune hiki ke alakaʻi i kahi hoʻoponopono ākea o ka autoimmunity," kākau nā mea noiʻi.

Ma kahi noiʻi hihia ʻē aʻe i paʻi ʻia ma Iune, ua hoʻohana nā mea noiʻi i nā pūnaewele CAR-T i hoʻopaʻa ʻia e CD-19 e mālama i kahi kanaka 41 makahiki me ka refractory antisynthetase syndrome me ka myositis holomua a me ka maʻi ʻāʻī interstitial. ʻEono mahina ma hope o ka mālama ʻana, ʻaʻohe hōʻailona o ka myositis ma MRI a ua hōʻike ʻia kahi hōʻike CT umauma i ka regression piha o ka alveolitis.

Mai ia manawa, ua hāʻawi mua ʻia ʻelua mau hui biotechnology - Cabaleta Bio ma Philadelphia a me Kyverna Therapeutics ma Emeryville, Kaleponi - i nā inoa wikiwiki mai ka US Food and Drug Administration no CAR T-cell therapy no SLE a me lupus nephritis. Ke alakaʻi nei ʻo Bristol-Myers Squibb i kahi hoʻāʻo pae 1 i nā poʻe maʻi me ka SLE koʻikoʻi, refractory. Ke hana nei kekahi mau hui biotechnology a me nā halemai ma Kina i nā hoʻokolohua lapaʻau no SLE. Akā,ʻo kēia wale nō ka piko o ka hau hau e pili ana i nā lāʻau lapaʻau no ka maʻi autoimmune, i'ōleloʻiaʻo Max Konig, MD, PhD, he loea kōkua o ka lāʻau lapaʻau ma ka māhele o ka rheumatology ma Johns Hopkins University School of Medicine ma Baltimore.

"He manawa hoihoi loa ia. ʻAʻole i ʻike ʻia ma ka mōʻaukala o ka autoimmunity, "i ʻōlelo ai ʻo ia.

He "Reboot" no ka Pūnaehana Immune

Ua puni nā lāʻau lapaʻau B-cell mai ka makahiki 2000 me nā lāʻau lapaʻau e like me rituximab, kahi lāʻau antibody monoclonal e kuhikuhi ana i ka CD20, kahi antigen i hōʻike ʻia ma ka ʻili o nā cell B. Loaʻa nā pūnaewele CAR T i kēia manawa i kahi antigen ʻē aʻe, CD19, a ʻoi aku ka ikaika o ka lāʻau lapaʻau. He mea maikaʻi nā mea ʻelua i ka hoʻopau ʻana i nā cell B i loko o ke koko, akā hiki i kēia mau ʻenekini CD19-targeted T cell ke hiki i nā cell B e noho ana i loko o nā ʻiʻo ma ke ʻano ʻaʻole hiki i nā antibody therapy, wehewehe ʻo Konig.